Combination chemoprevention, chronic diseases, cancer, diabetes, cardiovascular disease,molecular mechanisms, synergisms, Combinatie chemopreventie, chronische ziekten, kanker, diabetes, hartvaat ziekten, moleculaire mechanismen, synergie
Conditions
Sponsors
Maastricht University
Eligibility
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: - Healthy men or women with a Body Mass Index (BMI) between 18.5 and 27; - Between 18-60 years old.
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - Alcohol abuse up to 6 months before participation in this research, i.e. more than 4 drinks on any single day and more than 14 drinks per week for men and more than 3 drinks on any single day and more than 7 drinks per week for women; - Current presence of any diseases related to the gastrointestinal tract, kidney, liver, heart or lungs; - Current presence of type I or type II diabetes; - Current presence of symptoms related to diseases of the gastrointestinal tract, i.e. vomiting, diarrhea or constipation, and altered stool, such as blood in stool; - Current presence of diseases related to the endocrine or metabolic system; - Current presence of anemia; - HIV infection or hepatitis; - Use of antibiotics and other medication (except contraceptives) over the last 3 months; - Use of dietary supplements during the 3 months before start of the study; - Known allergies for fruits and/or vegetables - Current smokers and ex-smokers who stopped during the 3 months before start of the study; - Vegetarians and vegans; - Pregnant women; - Sportsmen and sportswomen who are physically active for more than 8 hours per week - Participants of other intervention studies during this intervention period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| -The level of oxidative DNA damage in ex-vivo treated lymphocytes -Oxidative stress parameters -Cardiovascular risk parameter: changes in microcirculation -Whole genome gene expression analyses -Evaluation of the prevalence of different polymorphisms | — |
Secondary
| Measure | Time frame |
|---|---|
| Optional parameters: The level of different plasma lipid levels such as cholesterol by measuring total cholesterol, high density lipoproteins (HDL), and low density lipoproteins (LDL), and triglycerides using standard kits; - The level of plasma homocysteine by means of ELISA; - Platelet activation by measuring platelet factor 4 and P-selectin in plasma using ELISA; - Immune response markers, like TNF-, interleukin-6, and C-reactive protein, using ELISA; - The level of fasting glucose and insulin levels in plasma in order to quantify insulin resistance and beta-cell function by means of Homeostatic model assessment (HOMA model). - bioavailability of different phytochemicals in the different interventions measured in plasma - white blood cell count | — |
Contacts
Public ContactS.G.J. van Breda
P.O. Box 616, School for Oncology and Developmental, Department of Toxicogenomics, Maastricht University Medical Centre +
Outcome results
None listed